Weight Loss After Bariatric Surgery Significantly Improves Carotid and Cardiac Function in Apparently Healthy People with Morbid Obesity - Scorecard - MDSpire
Advertisement
Weight Loss After Bariatric Surgery Significantly Improves Carotid and Cardiac Function in Apparently Healthy People with Morbid Obesity
Clinical Scorecard: Bariatric Surgery-Induced Weight Loss Leads to Notable Enhancements in Carotid and Cardiac Function Among Morbidly Obese Individuals Without Apparent Health Issues
At a Glance
Category
Detail
Condition
Morbid obesity with no apparent hypertension, diabetes, or cardiovascular disease
Key Mechanisms
Weight loss via diet and bariatric surgery improves arterial stiffness (carotid distensibility and pulse wave velocity) and cardiac function independent of blood pressure changes
Target Population
Morbidly obese adults (BMI ≥ 40 kg/m2) without hypertension, diabetes, or systemic disease
Care Setting
University hospital clinical setting with ultrasound and echocardiographic evaluation
Key Highlights
Bariatric surgery leads to significant weight loss and improvements in carotid artery compliance and cardiac indices in morbidly obese patients.
Arterial stiffness, measured by local carotid pulse wave velocity and distensibility, improves after diet and further after bariatric surgery independent of blood pressure changes.
Cardiac function parameters including stroke volume, cardiac output, and left ventricular structure and function improve following weight loss interventions.
Guideline-Based Recommendations
Diagnosis
Assess morbid obesity patients for cardiovascular risk factors even if asymptomatic.
Use carotid ultrasound and echocardiography to evaluate arterial stiffness and cardiac function pre- and post-weight loss interventions.
Measure brachial blood pressure and anthropometry (BMI, BSA) at baseline and follow-up.
Management
Implement dietary weight loss as initial intervention to improve vascular and cardiac function.
Consider bariatric surgery for sustained and greater weight loss in morbidly obese patients without contraindications.
Monitor improvements in arterial stiffness and cardiac function as markers of cardiovascular risk reduction.
Monitoring & Follow-up
Perform serial ultrasound and echocardiographic assessments at baseline, post-diet (~1 month), and post-bariatric surgery (~8 months).
Monitor blood pressure, glucose tolerance, and lipid profiles alongside vascular and cardiac parameters.
Evaluate left ventricular mass index, relative wall thickness, and diastolic function indices to track cardiac remodeling.
Risks
Exclude patients with hypertension, diabetes, atrial fibrillation, heart failure, or prior ischemic events from bariatric surgery without thorough evaluation.
Monitor for potential complications related to surgery and cardiovascular changes during weight loss.
Recognize that arterial stiffness improvements may be influenced by blood pressure changes; interpret results accordingly.
Patient & Prescribing Data
Morbidly obese adults without overt cardiovascular or metabolic disease
Weight loss via diet and bariatric surgery effectively improves vascular compliance and cardiac function, supporting surgical intervention in appropriate candidates.
Clinical Best Practices
Use a multidisciplinary approach including dietitians, cardiologists, and surgeons for managing morbid obesity.
Standardize measurement protocols for blood pressure, carotid ultrasound, and echocardiography to ensure reproducibility.
Apply non-invasive local carotid pulse wave velocity (lnDU-loop method) and arterial distensibility calculations for vascular assessment.
Evaluate cardiac function comprehensively including stroke volume, cardiac output, LV mass index, and diastolic function parameters.
Schedule follow-up assessments at defined intervals post-diet and post-surgery to monitor cardiovascular improvements.
by Alessandro Giudici, Carlo Palombo, Michaela Kozakova, Carmela Morizzo, Lorenzo Losso, Monica Nannipieri, Rossana Berta, Alun D. Hughes, J. Kennedy Cruickshank, Ashraf W. Khir
A pharmacovigilance analysis of FDA adverse event reports finds the strongest ischemic optic neuropathy reporting signal with high-dose semaglutide formulations, with higher adjusted odds reported in men.